^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Triple Negative Breast Cancer
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

    Excerpt:
    ...Disease free survival`Disease free survival in PD-L1-positive patients...
    Trial ID:
    A-Brave
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

    Excerpt:
    Avelumab showed an acceptable safety profile and had clinical activity in a subset of pts with MBC. In pts with TNBC, presence of PD-L1 expressing immune cells within the tumor may be associated with clinical responses to avelumab
    DOI:
    10.1158/1538-7445.SABCS15-S1-04
    Trial ID:
    JAVELIN Solid Tumor